Literature DB >> 9474068

Empirical comparison of the results of randomized controlled trials and case-control studies in evaluating the effectiveness of screening mammography.

K Demissie1, O F Mills, G G Rhoads.   

Abstract

The gold standard for evaluating screening programs is the randomized controlled trial (RCT). Case-control studies are easier to perform but their role in this area is controversial. The purpose of this article is to compare empirically the results of RCTs and case-control studies conducted to evaluate the efficacy and effectiveness of screening mammography and examine possible explanations for differences in their results. We located eight RCTs and five case-control studies of screening mammography. For women aged 40-74 years at screening, comparison of the summary risk estimates of the RCTs (0.76, 95% CI: 0.69-0.83) with that of the case-control studies (0.44, 95%, CI: 0.38-0.50) showed RCTs to have a significantly higher summary risk estimate than case-control studies (ratio = 1.74, 95% CI: 1.48-2.04). It is notable that the RCTs were compromised in most instances by low compliance rates (50-80%) in the treatment groups and by significant use of screening in the control groups (20-30%). Adjustment of the RCT results for these cross-overs yields results that are in reasonable agreement with the summary estimate for the case-control studies. These findings support the use of case-control studies to estimate the efficacy of mammographic screening where RCTs are not feasible. They suggest that the efficacy of mammography in women aged 50 years and above is somewhat greater than the effectiveness measured by the intent-to-treat analysis of RCTs.

Entities:  

Mesh:

Year:  1998        PMID: 9474068     DOI: 10.1016/s0895-4356(97)00243-6

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  17 in total

1.  Randomized, controlled trials, observational studies, and the hierarchy of research designs.

Authors:  J Concato; N Shah; R I Horwitz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

Review 2.  Observational versus experimental studies: what's the evidence for a hierarchy?

Authors:  John Concato
Journal:  NeuroRx       Date:  2004-07

Review 3.  The benefits and harms of breast cancer screening: an independent review.

Authors:  M G Marmot; D G Altman; D A Cameron; J A Dewar; S G Thompson; M Wilcox
Journal:  Br J Cancer       Date:  2013-06-06       Impact factor: 7.640

4.  Radiation risk of breast screening in England with digital mammography.

Authors:  Lucy M Warren; David R Dance; Kenneth C Young
Journal:  Br J Radiol       Date:  2016-09-21       Impact factor: 3.039

5.  Age-based versus Risk-based Mammography Screening in Women 40-49 Years Old: A Cross-sectional Study.

Authors:  Elizabeth S Burnside; Amy Trentham-Dietz; Christina M Shafer; John M Hampton; Oguz Alagoz; Jennifer R Cox; Eric Mischo; Sarina B Schrager; Lee G Wilke
Journal:  Radiology       Date:  2019-06-11       Impact factor: 11.105

6.  Prostate-specific antigen screening and mortality from prostate cancer.

Authors:  Stephen W Marcella; George G Rhoads; Jeffrey L Carson; Frances Merlino; Homer Wilcox
Journal:  J Gen Intern Med       Date:  2008-01-03       Impact factor: 5.128

7.  Evaluating Population-Based Screening Mammography Programs Internationally.

Authors:  Carrie N Klabunde; Rachel Ballard-Barbash
Journal:  Semin Breast Dis       Date:  2007-06

Review 8.  The outcomes movement and evidence-based medicine in plastic surgery.

Authors:  Evan Kowalski; Kevin C Chung
Journal:  Clin Plast Surg       Date:  2012-11-26       Impact factor: 2.017

Review 9.  Prevention trials: their place in how we understand the value of prevention strategies.

Authors:  Graham A Colditz; Philip R Taylor
Journal:  Annu Rev Public Health       Date:  2010       Impact factor: 21.981

Review 10.  Antimicrobial agent exposure and the emergence and spread of resistant microorganisms: issues associated with study design.

Authors:  C Angebault; A Andremont
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-12-27       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.